RT @gasingiltv: #GI_Cancer #ESMO22 #CDH17 is an attractive target for GI cancer. Some companies are in phase 1 clinical trials with #BsAb.…
#GI_Cancer #ESMO22 #CDH17 is an attractive target for GI cancer. Some companies are in phase 1 clinical trials with #BsAb. We will see the initial data of B1 905711 (CDH17×#TRAILR2) in ESMO22. ➡️https://t.co/fEMHwaxtR2
RT @candacewslei1: Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel…
RT @MCT_AACR: BI 905711, a bispecific antibody targeting TRAILR2 and CDH17, has potent and selective #AntitumorActivity in CDH17-positive #…
RT @MCT_AACR: BI 905711, a bispecific antibody targeting TRAILR2 and CDH17, has potent and selective #AntitumorActivity in CDH17-positive #…
RT @MCT_AACR: BI 905711, a bispecific antibody targeting TRAILR2 and CDH17, has potent and selective #AntitumorActivity in CDH17-positive #…
RT @MCT_AACR: BI 905711, a bispecific antibody targeting TRAILR2 and CDH17, has potent and selective #AntitumorActivity in CDH17-positive #…
BI 905711, a bispecific antibody targeting TRAILR2 and CDH17, has potent and selective #AntitumorActivity in CDH17-positive #ColorectalCancer models both in vitro and in vivo. Paper by Garcia-Martinez. @Boehringer @JM_GaMar @norbertkraut1 https://t.co/Ts
BI 905711, a bispecific antibody targeting TRAILR2 and CDH17, has potent and selective #AntitumorActivity in CDH17-positive #ColorectalCancer models both in vitro and in vivo. Paper by Garcia-Martinez @Boehringer @JM_GaMar @norbertkraut1 https://t.co/bz0
RT @MCT_AACR: BI 905711, a bispecific antibody targeting TRAILR2 and CDH17, has potent and selective #AntitumorActivity in CDH17-positive #…
BI 905711, a bispecific antibody targeting TRAILR2 and CDH17, has potent and selective #AntitumorActivity in CDH17-positive #ColorectalCancer models both in vitro and in vivo. Paper by Garcia-Martinez @Boehringer @JM_GaMar @norbertkraut1. https://t.co/IN
RT @norbertkraut1: Check out key preclinical data on our tumor-targeted clinical-stage TRAILR2 agonist in @MCT_AACR Congrats to the entire…
RT @norbertkraut1: Check out key preclinical data on our tumor-targeted clinical-stage TRAILR2 agonist in @MCT_AACR Congrats to the entire…
Link to paper: https://t.co/npYxAe6xgu From: @norbertkraut1, @Boehringer
RT @norbertkraut1: Check out key preclinical data on our tumor-targeted clinical-stage TRAILR2 agonist in @MCT_AACR Congrats to the entire…
RT @norbertkraut1: Check out key preclinical data on our tumor-targeted clinical-stage TRAILR2 agonist in @MCT_AACR Congrats to the entire…
Check out key preclinical data on our tumor-targeted clinical-stage TRAILR2 agonist in @MCT_AACR Congrats to the entire team @Boehringer and key collaborators
BI 905711, a bispecific antibody targeting TRAILR2 and CDH17, has potent and selective #AntitumorActivity in CDH17-positive #ColorectalCancer models both in vitro and in vivo. Article by Garcia-Martinez. @Boehringer @JM_GaMar @norbertkraut1 https://t.co/
Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist https://t.co/Gd61Ow1jFF